

# News Release

FOR IMMEDIATE RELEASE

## **Hitachi High-Tech America, Inc. Announces that Nitin Baliga, M.Sc., Ph.D., Myla Lai-Goldman, M.D., and Tomi Pastinen, M.D., Ph.D., Join its Newly Created Scientific Advisory Board**

*Multidisciplinary Team Expected to Provide Strategic Guidance and Direction for Hitachi High-Tech America's Molecular Research and Development Division*

Santa Clara, CA, February 22, 2024—Hitachi High-Tech America, Inc. (HTA) announced it has assembled a group of scientific and industry experts to form a Scientific Advisory Board (SAB). The formation of HTA's SAB follows strategic investments by HTA's Japanese parent company, Hitachi High-Tech Corporation, in [Nabsys 2.0 LLC](#) and [Invivoscribe, Inc.](#), and supports HTA's mission to advance molecular research and diagnostics, as well as precision and digital medicine.

HTA selected SAB members for their leadership in fields such as systems biology, molecular clinical diagnostics, and clinical pathology. HTA intends that the SAB members' service will provide strategic guidance and direction for HTA's pursuit of new investments, products, and services. The SAB is comprised of the following members:

**Nitin Baliga, M.Sc., Ph.D. — Professor, SVP, and Director at Institute for Systems Biology, and President, Baliga Consulting LLC**

Nitin Baliga leads a cross-disciplinary team of scientists to address complex problems relevant to global health, personalized medicine, and the environment. His team uses a systems approach to construct predictive models of cellular and molecular networks within pathogens, cancer cells, and environmental microbes to enable biotechnologies to overcome drug resistance, find new drugs, predict consequences of climate change, and manufacture biorenewables. Dr. Baliga's laboratory has received research support from the National Science Foundation, the National Institutes of Health, NASA, the U.S. Department of Energy, the U.S. Department of Defense, the Bill and Melinda Gates Foundation, and the Paul G. Allen Family Foundation. He has served in editorial roles

for many journals, including BMC Systems Biology, Applied and Environmental Microbiology, Royal Society Open Science, and Nature Scientific Data. He serves on the scientific advisory boards of numerous academic and industrial organizations, and has been instrumental in research program planning for the National Science Foundation and U.S. Department of Energy.

**Myla Lai-Goldman, M.D. — Co-Founder and Chairperson at GeneCentric Therapeutics, Inc.**

Dr. Lai-Goldman has over 30 years' experience in the development, commercialization, and adoption of novel molecular diagnostic assays. She co-founded GeneCentric Therapeutics, a company leveraging deep RNA expertise to develop the rT(I)ME Explorer Platform, utilizing advanced computational biology to define cancer subtypes, biomarkers, and immune profiles, that explore the tumor and its associated microenvironment. Prior to GeneCentric Therapeutics, Dr. Lai-Goldman was Executive Vice President and Chief Medical Officer of Laboratory Corporation of America® Holdings (LabCorp®), where she managed LabCorp's National Office of Quality and Science, through which she was responsible for all quality, science, and medical activities for LabCorp and its subsidiaries.

**Tomi Pastinen, M.D., Ph.D. — Director of the Genomic Medicine Center at Children's Mercy Kansas City**

Dr. Pastinen has been the Director of the **Genomic Medicine Center** of Children's Mercy Kansas City since 2017. Dr. Pastinen joined Children's Mercy from McGill University. He held the Canada Research Chair from 2007 to 2017. He has authored over 200 peer-reviewed publications, including papers in the top-tier journals Cell and Nature Genetics. Prior to joining Children's Mercy, he led the epigenome mapping center at McGill as part of the International Human Epigenome Consortium, which provides maps of genome function to the global research community. Since 2019, Dr. Pastinen has led the Genomic Answers for Kids program, a foundational initiative for future genomic research at Children's Mercy that aims to learn from 30,000 children with genetic conditions. He is a co-founding member of ColorsDB, a global initiative to build a reference variation database from long-read human genomes.

"The formation of an SAB is a significant milestone in Hitachi High-Tech's mission to become a global leader in molecular diagnostics and drive the advancement of precision medicine,"

said Tsuyoshi Ogino, General Manager of HTA's Molecular Research and Diagnostics Division. "The collective expertise and forward thinking of the SAB members will help guide our product development and future investments as we execute on our mission."

**About Hitachi High-Tech America, Inc.**

Hitachi High-Tech America, Inc. (HTA) is a privately-owned global affiliate company that operates within the Hitachi Group companies. HTA sells and services semiconductor manufacturing equipment, analytical instrumentation, scientific instruments, and bio-related products as well as industrial equipment, electronic devices, and electronic and industrial materials. HTA is dedicated to successful and profitable collaboration with leading companies worldwide with a direction towards providing customers with superior quality products and services at fair and competitive prices. For more information, please visit <https://www.hitachi-hightech.com/us/en/>.

**Media Contact**

Brand & Marketing

Hitachi High-Tech America, Inc.

Email: [hta-marketing@hitachi-hightech.com](mailto:hta-marketing@hitachi-hightech.com)